Symbio Announces Phase I Clinical Unit

July 1, 2008

Company News Release

Symbio LLC, a full service contract research organization, has announced the opening of a new Phase I Clinical Unit in Michigan City, Indiana.

Port Jefferson, NY – Symbio LLC, a full service contract research organization, has announced the opening of a new Phase I Clinical Unit. Since 2002, Symbio has provided services to pharmaceutical, generic and medical device companies that have resulted in many successful clinical trials. Services provided by Symbio include: clinical trial management, biometrics, strategic consulting, product development and topical formulation development. With the addition of the Phase I Unit, a key component to the complete clinical development process, Symbio now has the ability to provide development from Phase I through Phase IV.


In collaboration with Saint Anthony Memorial Hospital in Michigan City, Indiana, the Phase I Unit is a 62 bed capacity facility and is located within the confines of Saint Anthony Memorial Hospital. The hospital provides an entire floor devoted to the conduct of Phase I studies, ensuring the highest quality medical care and safety standards.

Symbio has long-standing, special expertise working with the generic drug industry. The Symbio Phase I Clinical Team is set up to prepare and execute clinical plans to support FDA approval of generic products.
Symbio’s Phase I Unit at Saint Anthony Memorial Hospital is centrally located in northwest Indiana, between the Illinois and Michigan state borders.

Just 45 minutes from downtown Chicago, diverse populations of healthy participants are easily accessible including eight local colleges/universities and technical schools.


For further information contact: Edward Drower, Director of Phase I Clinical Operations
Phone: 219-861-8817, Email: edrower@symbioresearch.com

Related Content:

News